---
title: "STOCKS | Zhaoyan New Drug Warns of Overheated Sentiment and Irrational Speculation Risk"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292880698.md"
description: "Zhaoyan New Drug warned of overheated sentiment and irrational speculation risks after its stock surged over 20% in three days. The company cautioned that short-term gains were large, the risk of decline is high, and biological asset values face significant fluctuation uncertainties due to multiple factors."
datetime: "2026-07-16T08:57:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292880698.md)
  - [en](https://longbridge.com/en/news/292880698.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292880698.md)
generator: "portal-rs"
---

# STOCKS | Zhaoyan New Drug Warns of Overheated Sentiment and Irrational Speculation Risk

Zhaoyan New Drug said its stock rose sharply over three straight trading days from July 14 to July 16, 2026, with the cumulative deviation in closing-price gains exceeding 20%. According to Jin10, the company warned that short-term gains had been large, market sentiment may be overheated, and irrational speculation risk remained high, with the stock facing a risk of decline at any time. The company also said the fair value of its biological assets was affected by multiple uncertainties and carried a significant risk of value fluctuations.

### Related Stocks

- [603127.CN](https://longbridge.com/en/quote/603127.CN.md)
- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)

## Related News & Research

- [JOINN Laboratories Flags Surging Interim Profit on Biological Asset Gains](https://longbridge.com/en/news/292628989.md)
- [Precision Peptide to showcase Recovery Patch at FitExpo Anaheim](https://longbridge.com/en/news/296902176.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [05:13 ETKeymed Biosciences Announces 2026 H1 Results and Business Updates](https://longbridge.com/en/news/296594656.md)
- [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**